Table 1.
Demographic and clinical characteristics at t0 (at starting omalizumab) (N = 143)
| Characteristic | All patients (n:143)a |
|---|---|
| Age, median (IQR) | 44 (24–57) |
| Sex, female, n (%) | 96 (66.6) |
| Body Mass Index, median (IQR) | 25.52 (24.36–27.47) |
| Type of health insurance affiliation, n (%) | |
| Contributory | 125 (87.4) |
| Special regimen | 12 (8.4) |
| Subsidized | 5 (3.5) |
| Other | 1 (0.7) |
| Cities and sites, n (%) | |
| Bogotá, 2 sites | 89 (62.2) |
| Bucaramanga, 1 site | 25 (17.5) |
| Pereira, 1 site | 10 (7) |
| Medellín, 2 sites | 10 (7) |
| Cali, 1 site | 5 (3.5) |
| Barranquilla, 1 site | 4 (2.8) |
| Comorbidities, n (%) | |
| Rhinitis | 91 (64.1) |
| Sinusitis | 27 (18.9) |
| Nasal polyposis | 24 (16.9) |
| Gastroesophageal reflux | 15 (10.6) |
| Other comorbidities | 90 (63.4) |
| Eosinophils blood count, n (%) | |
| < 300 cells/μL | 41 (51.9) |
| ≥ 300 cells/μL | 38 (48.1) |
| IgE, serum levels, n (%) | |
| < 30 UI/mL | 2 (1.6) |
| ≥ 30 UI/mL | 118 (98.4) |
| Prick test result, n (%) | |
| Positive | 71 (84.5) |
| Negative | 13 (15.4) |
| Severe asthma classification criteria, n (%) | |
| Steps 4 or 5 or use SC in more than 50% of the previous year | 116 (81.1) |
| High doses of IC or SC to keep asthma under control | 27 (18.8) |
| GINA assessment for asthma control, n (%) | |
| Uncontrolled | 76 (76) |
| Partly controlled | 16 (16) |
| Well controlled | 8 (8) |
| Deworming 12 months before t − 0, n (%) | |
| Yes | 8 (5.6) |
| No | 29 (20.3) |
| No data | 106 (74.1) |
aAs it is explained in the text, not all the patients had a registered value of eosinophils, IgE and/or Prick test at starting omalizumab